DiaMedica Therapeutics Inc.

NasdaqCM:DMAC Rapporto sulle azioni

Cap. di mercato: US$178.8m

DiaMedica Therapeutics Gestione

Gestione criteri di controllo 3/4

DiaMedica Therapeutics Il CEO è Rick Pauls, nominato in Jan2010, e ha un mandato di 14.83 anni. la retribuzione annua totale è $ 1.22M, composta da 46.2% di stipendio e 53.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.16% delle azioni della società, per un valore di $ 286.70K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.2 anni e 5.5 anni.

Informazioni chiave

Rick Pauls

Amministratore delegato

US$1.2m

Compenso totale

Percentuale dello stipendio del CEO46.2%
Mandato del CEO14.8yrs
Proprietà del CEO0.2%
Durata media del management2.2yrs
Durata media del Consiglio di amministrazione5.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

May 16
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

Jan 12
We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold

Jul 06

We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate

Jun 16
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate

We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

Jan 04
We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.

Nov 05

DiaMedica: Undercovered Stroke Drug Company With Decent Data

Jun 13

We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth

May 01
We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth

Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful?

Feb 13
Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful?

We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn

Jan 09
We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn

DiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Rick Pauls rispetto agli utili di DiaMedica Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$22m

Jun 30 2024n/an/a

-US$20m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$1mUS$562k

-US$19m

Sep 30 2023n/an/a

-US$18m

Jun 30 2023n/an/a

-US$17m

Mar 31 2023n/an/a

-US$15m

Dec 31 2022US$1mUS$523k

-US$14m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$14m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$1mUS$477k

-US$14m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021n/an/a

-US$14m

Mar 31 2021n/an/a

-US$13m

Dec 31 2020US$878kUS$455k

-US$12m

Sep 30 2020n/an/a

-US$11m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019US$2mUS$420k

-US$11m

Sep 30 2019n/an/a

-US$10m

Jun 30 2019n/an/a

-US$9m

Mar 31 2019n/an/a

-US$8m

Dec 31 2018US$734kUS$315k

-US$6m

Sep 30 2018n/an/a

-US$5m

Jun 30 2018n/an/a

-US$4m

Mar 31 2018n/an/a

-US$4m

Dec 31 2017US$502kUS$280k

-US$4m

Compensazione vs Mercato: La retribuzione totale di Rick ($USD 1.22M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 1.46M ).

Compensazione vs guadagni: La retribuzione di Rick è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Rick Pauls (53 yo)

14.8yrs

Mandato

US$1,215,161

Compensazione

Mr. Dietrich John Pauls, also known as Rick, MBA has been Chief Executive Officer and President of DiaMedica Therapeutics Inc. since January 2010 and has been its Director since April 2005. Mr. Pauls was a...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Dietrich Pauls
President14.8yrsUS$1.22m0.16%
$ 286.7k
Scott Kellen
CFO & Corporate Secretary6.6yrsUS$632.22k0.075%
$ 135.0k
Ambarish Shah
Chief Technology Officer1.2yrsNessun datoNessun dato
Dominic Cundari
Chief Commercial Officer2.8yrsNessun dato0.0066%
$ 11.7k
David Wambeke
Chief Business Officer1.6yrsNessun dato1.23%
$ 2.2m
Lorianne Masuoka
Chief Medical Officerless than a yearNessun datoNessun dato

2.2yrs

Durata media

59yo

Età media

Gestione esperta: Il team dirigenziale di DMAC è considerato esperto (durata media dell'incarico 2.2 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Dietrich Pauls
President19.6yrsUS$1.22m0.16%
$ 286.7k
James Parsons
Independent Director9.1yrsUS$97.18k0.0053%
$ 9.4k
R. Giuffre
Independent Director14.3yrsUS$90.93k0.76%
$ 1.3m
George L. Bakris
Member of Kidney Scientific Advisory Board5.5yrsNessun datoNessun dato
Richard Pilnik
Independent Chairman15.5yrsUS$133.98k0.33%
$ 591.3k
Glenn Chertow
Member of Kidney Scientific Advisory Board5.5yrsNessun datoNessun dato
Rajiv Agarwal
Member of Kidney Scientific Advisory Board5.5yrsNessun datoNessun dato
Philip Bath
Member of Stroke Advisory Board1.8yrsNessun datoNessun dato
Scott Kasner
Member of Stroke Clinical Advisory Boardno dataNessun datoNessun dato
Charles Herzog
Member of Kidney Scientific Advisory Boardno dataNessun datoNessun dato
John Volpi
Member of Stroke Clinical Advisory Boardno dataNessun datoNessun dato
Aldo Peixoto
Member of Kidney Scientific Advisory Board5.5yrsNessun datoNessun dato

5.5yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di DMAC sono considerati esperti (durata media dell'incarico 5.5 anni).